Moderna (MRNA)
(Real Time Quote from BATS)
$138.31 USD
+5.41 (4.07%)
Updated May 20, 2024 11:28 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRNA 138.31 +5.41(4.07%)
Will MRNA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRNA
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Stock Market News for May 14, 2024
Other News for MRNA
Moderna Inc (MRNA)'s Uncertain Future: Understanding the Barriers to Outperformance
Wall Street Breakfast: What Moved Markets
Novo Nordisk, J&J lead R&D rankings in big pharma: report
10 Health Care Stocks Whale Activity In Today's Session
Moderna vaccine patent upheld by European Patent Office: report